QMS Medical Allied Services Ltd

QMS Medical experienced significant growth from March 2024 to March 2025, with net sales rising to 156.01 Cr and profit after tax increasing to 13.70 Cr. The company also saw improvements in operating profit and cash flow from operating activities, despite a decline in cash flow from investing activities.

QMS Medical experienced significant growth from March 2024 to March 2025, with net sales increasing to 156.01 Cr and profit after tax rising to 13.70 Cr. The company also improved its operating profit margin to 16.29% and earnings per share to 6.7.

As of 10-Nov, QMS Medical Allied Services Ltd's stock price is declining at 93.70, down 3.4%, with a year-to-date drop of 17.41%. Despite this, the company shows strong long-term growth potential, attracting increased institutional investment and trading at a discount compared to peers.

As of 17-Oct, QMS Medical Allied Services Ltd's stock price is declining at 99.80, down 1.43%, and has underperformed its sector. Despite recent losses, the company shows strong long-term growth potential, with increasing profits and an attractive valuation compared to peers.

QMS Medical experienced significant growth from March 2024 to March 2025, with net sales rising to 156.01 Cr, profit after tax increasing to 13.70 Cr, and earnings per share improving to 6.77. The company also reported enhanced operating profit margins and a substantial increase in cash flow from operating activities.

As of 08-Oct, QMS Medical Allied Services Ltd is currently priced at 107.15, reflecting a recent upward trend despite underperforming its sector today. While the stock has shown strong short-term performance compared to the Sensex, concerns about rising interest expenses and declining investor participation may affect its future outlook.

As of 24-Sep, QMS Medical Allied Services Ltd is priced at 99.90, showing a recent mixed performance with a weekly decline of 6.64% but a monthly rise of 18.72%. Despite long-term growth and an attractive valuation, the stock faces challenges with decreased investor participation and underperformance relative to the market.

As of 23-Sep, QMS Medical Allied Services Ltd is priced at 98.85, down 6.08%, with a significant decline in delivery volume and underperformance compared to its sector and the broader market. Despite a strong long-term growth rate and attractive valuation, the stock has faced a 25.40% drop over the past year, reflecting declining investor confidence.

As of 22-Sep, QMS Medical Allied Services Ltd is priced at 105.25, down 2.86%. Despite strong short-term performance and positive momentum, the stock has underperformed over the past year, raising concerns for investors.

As of 19-Sep, QMS Medical Allied Services Ltd is priced at 108.35, showing a short-term performance improvement with a 1-week return of +18.42% and a 1-month return of +36.98%, despite a decline in investor participation. The stock is trading above key moving averages and has strong long-term growth, although it has underperformed over the past year.

As of 18-Sep, QMS Medical Allied Services Ltd is priced at 105.90, down 1.03%, and has underperformed its sector by 4.01%. Despite a year-to-date decline of 6.65% and a one-year drop of 22.84%, the company shows strong long-term growth in operating profit, indicating a potentially attractive valuation.

As of 17-Sep, QMS Medical Allied Services Ltd is currently priced at 107.00, reflecting a 6.4 increase and strong recent performance, outperforming its sector and gaining 17.26% over the past week. Despite a year-to-date decline, the stock shows potential as it trades at a discount to peers and has experienced significant growth in operating profits.

As of 15-Sep, QMS Medical Allied Services Ltd is currently priced at 93.15, reflecting a 1.8% increase, and has outperformed its sector today. Despite a year-to-date decline of -17.89%, the company shows strong long-term growth potential with a 30.17% annual growth rate in operating profit.